Penile squamous cell carcinoma (PSCC) is a rare tumor with an aggressive behavior. The Meet-URO 23/I-RARE registry includes rare genitourinary malignancies. We extracted patients with PSCC to conduct a retrospective study aimed at assessing clinical outcomes and prognostic factors.
Primary endpoints were overall survival and progression-free survival. Prognostic factors for OS and PFS were analyzed using univariate and multivariate analysis. From the Meet-URO 23/I-RARE database, we extracted 128 patients with diagnosis of PSCC. About 48% of patients underwent first-line of therapy.
In the overall population, median OS from diagnosis was 34.6 months. Significant differences in median OS were observed according to ECOG PS at diagnosis (57.3 months vs. 8.3 months; P < .001), and median age (≤77y 88.8 months vs. >77y 26 months; P = .013). At multivariate analysis, ECOG PS 2-4 at diagnosis (HR 3.04) and lymph node metastases (HR 2.49) were independently associated with a higher risk of death. Among patients undergoing first-line therapy (n = 61), median OS was 12.3 months, and a statistically significant difference was found according to type of response to first-line (DCR 24.4 months vs. PD 7.1 months; P < .001). Multivariate analysis showed that only age >77 years was associated with a worse OS (HR 2.16). A statistically significant difference in PFS was found according to platinum plus 5-fluorouracil versus platinum plus taxane (4.9 vs. 3.4 months; P = .036) and regimens with 2 versus 3 drugs (3.4 vs. 8.6 months; P = .019). At the multivariate analysis only regimens with platinum plus taxane were associated with worse PFS (HR 2.83).
In our registry study, PSCC is confirmed to be an aggressive disease. Poor ECOG PS, presence of lymph node metastases, and higher age at diagnosis appear to be associated with worse survival outcomes.
Clinical genitourinary cancer. 2024 Mar 18 [Epub ahead of print]
Veronica Mollica, Francesco Massari, Marco Maruzzo, Davide Bimbatti, Melanie Claps, Brigida Anna Maiorano, Maria Giuseppa Vitale, Roberto Iacovelli, Paola Ermacora, Giandomenico Roviello, Fabio Calabrò, Orazio Caffo, Francesca Vignani, Francesco Grillone, Francesco Pierantoni, Marilena Di Napoli, Alessia Mennitto, Andrea Marchetti, Alvise Mattana, Alessia Cavo, Maria Bassanelli, Luigi Formisano, Veronica Prati, Giulia Claire Giudice, Sebastiano Buti
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna - Italia; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. Electronic address: ., Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna - Italia; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy., Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy., Dipartimento di Oncologia Medica ed Ematologia, SSD Oncologia Medica Genitourinaria, Programma Prostata, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano., Oncology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy., Department of Oncology and Hematology, University Hospital of Modena, 41100 Modena, Italy., Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Dipartimento di Oncologia, Presidio Ospedaliero Universitario Santa Maria della Misericordia, Azienda sanitaria universitaria integrata Friuli Centrale, Udine, Italy., Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Firenze, Firenze, Italy., Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy., Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy., Division of Medical Oncology, Ordine Mauriziano Hospital, Torino, Italy., UO Oncologia - Azienda Ospedaliera Universitaria Renato Dulbecco, Catanzaro, Italy., Oncology 3 Unit, Department of Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy., Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy., SCDU Oncologia, "Maggiore della Carità " University Hospital, 28100 Novara, Italy., Oncology Unit, Villa Scassi Hospital, Genova, Italy., Medical Oncology, 1-IRCCS Regina Elena National Cancer Institute, Rome, Italy., Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80138 Naples, Italy., Department of Medical Oncology, Ospedale Michele e Pietro Ferrero, Verduno-Azienda Sanitaria Locale CN2, Alba-Bra, 12060 Cuneo, Italy., Medical Oncology Unit, University Hospital of Parma - Department of Medicine and Surgery, University of Parma, Parma, Italy.